Abiomed, Inc. (NASDAQ:ABMD) Shares Acquired by BlackRock Inc.

BlackRock Inc. lifted its stake in shares of Abiomed, Inc. (NASDAQ:ABMD) by 2.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,305,025 shares of the medical equipment provider’s stock after acquiring an additional 115,689 shares during the period. BlackRock Inc. owned 0.09% of Abiomed worth $1,401,371,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in Abiomed by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 4,880,019 shares of the medical equipment provider’s stock worth $1,523,103,000 after buying an additional 70,871 shares during the last quarter. Baillie Gifford & Co. boosted its stake in Abiomed by 2.8% in the 3rd quarter. Baillie Gifford & Co. now owns 3,733,710 shares of the medical equipment provider’s stock worth $1,215,397,000 after buying an additional 100,298 shares during the last quarter. State Street Corp boosted its stake in Abiomed by 3.0% in the 2nd quarter. State Street Corp now owns 1,955,193 shares of the medical equipment provider’s stock worth $610,235,000 after buying an additional 56,338 shares during the last quarter. Geode Capital Management LLC boosted its stake in Abiomed by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 792,812 shares of the medical equipment provider’s stock worth $246,759,000 after buying an additional 16,151 shares during the last quarter. Finally, Ownership Capital B.V. boosted its stake in Abiomed by 19.9% in the 3rd quarter. Ownership Capital B.V. now owns 724,443 shares of the medical equipment provider’s stock worth $235,821,000 after buying an additional 120,266 shares during the last quarter. 89.95% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have issued reports on the company. Zacks Investment Research raised Abiomed from a “sell” rating to a “hold” rating and set a $369.00 price target on the stock in a research note on Wednesday, November 17th. SVB Leerink restated a “hold” rating on shares of Abiomed in a report on Sunday, October 31st. Finally, Morgan Stanley raised their price objective on Abiomed from $269.00 to $292.00 and gave the stock an “underweight” rating in a report on Friday, January 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, Abiomed has an average rating of “Hold” and a consensus target price of $374.20.

Shares of NASDAQ:ABMD opened at $301.22 on Friday. The company has a market cap of $13.71 billion, a P/E ratio of 92.97, a PEG ratio of 3.64 and a beta of 1.29. Abiomed, Inc. has a one year low of $261.27 and a one year high of $387.40. The business’s 50-day simple moving average is $332.95 and its 200 day simple moving average is $337.47.

Abiomed (NASDAQ:ABMD) last announced its earnings results on Wednesday, October 27th. The medical equipment provider reported $1.03 EPS for the quarter, beating the consensus estimate of $0.98 by $0.05. The business had revenue of $248.10 million for the quarter, compared to the consensus estimate of $248.06 million. Abiomed had a return on equity of 15.80% and a net margin of 15.32%. The company’s revenue was up 18.3% on a year-over-year basis. During the same period last year, the business posted $1.01 EPS. Equities research analysts expect that Abiomed, Inc. will post 4.21 EPS for the current year.

In other Abiomed news, Director Martin P. Sutter sold 15,000 shares of Abiomed stock in a transaction that occurred on Thursday, November 18th. The stock was sold at an average price of $338.59, for a total transaction of $5,078,850.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Martin P. Sutter sold 3,750 shares of Abiomed stock in a transaction that occurred on Tuesday, November 16th. The stock was sold at an average price of $351.85, for a total value of $1,319,437.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 19,750 shares of company stock worth $6,757,718. Company insiders own 3.00% of the company’s stock.

Abiomed Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It distributes its products under the Impella brand. The company was founded by David M. Lederman in 1981 and is headquartered in Danvers, MA.

Featured Article: Overweight

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abiomed, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for Abiomed (NASDAQ:ABMD)

Receive News & Ratings for Abiomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed and related companies with MarketBeat.com's FREE daily email newsletter.